（文章来源：每日经济新闻） 国药股份（SH 600511，收盘价：30.01元）8月20日晚间发布半年度业绩报告称，2025年上半年营业收 入约256.34亿元，同比增加3.54%；归属于上市公司股东的净利润约9.49亿元，同比减少5.19%；基本每 股收益1.2572元，同比减少5.19%。 ...

Core Viewpoint - The company reported a revenue of 41.188 billion yuan for the first half of the year, reflecting a year-on-year growth of 3.54% [2] - The net profit attributable to shareholders reached 282 million yuan, marking an 18.56% increase compared to the previous year [2] - The basic earnings per share stood at 0.16 yuan [2] Financial Performance - Revenue for the first half of the year: 41.188 billion yuan, up 3.54% year-on-year [2] - Net profit attributable to shareholders: 282 million yuan, up 18.56% year-on-year [2] - Basic earnings per share: 0.16 yuan [2]

国药股份(600511.SH)发布2025年半年度报告，该公司营业收入为256.34亿元，同比增长3.54%。归属于 上市公司股东的净利润为9.49亿元，同比减少5.19%。归属于上市公司股东的扣除非经常性损益的净利 润为9.32亿元，同比减少7.14%。基本每股收益为1.2572元。 报告期内，公司持续加大科技创新力度，稳步推进重大科研项目，有力加速创新型企业建设。子公司国 瑞药业围绕现有77个在研项目，加速推进工业创新能力升级。子公司国药物流亦持续加大科技创新投 入，积极扩大知识产权成果，截至6月底，新增软件著作权6项，并成功提交发明专利申请1项。 ...

每经AI快讯，国药股份（SH 600511，收盘价：30.01元）8月20日晚间发布公告称，国药集团药业股份 有限公司董事会于2025年8月19日收到公司副总经理叶彤女士的书面辞职报告。叶彤女士因退休原因申 请辞去公司副总经理职务，辞职后不再担任公司任何职务。 2024年1至12月份，国药股份的营业收入构成为：医药商业占比104.55%，医药工业占比0.93%，仓储物 流占比0.78%，其他业务占比0.19%，内部抵销占比-6.45%。 截至发稿，国药股份市值为226亿元。 （记者 王晓波） 每经头条（nbdtoutiao）——最火游资不再是方新侠、章盟主、佛山无影脚？这名95后声名鹊起！ ...

格隆汇8月20日丨国药股份(600511.SH)公布2025年半年度报告，报告期实现营业收入256.34亿元，同比 增长3.54%；归属于上市公司股东的净利润9.49亿元，同比下降5.19%；归属于上市公司股东的扣除非经 常性损益的净利润9.32亿元，同比下降7.14%；基本每股收益1.2572元。 ...

Group 1 - The company, Zhongyao Holdings, announced the convening of its 17th meeting of the 9th board of directors on August 19, 2025, to discuss the proposal for the establishment of a compliance manual [1] - For the year 2024, the revenue composition of Zhongyao Holdings is as follows: pharmaceutical wholesale accounts for 95.03%, pharmaceutical retail accounts for 4.59%, and other businesses account for 0.38% [1] - As of the report date, the market capitalization of Zhongyao Holdings is 9.4 billion yuan [1]

Core Insights - The company reported a revenue of approximately 41.188 billion yuan for the first half of 2025, representing a year-on-year increase of 3.54% [2] - The net profit attributable to shareholders was approximately 282 million yuan, showing a year-on-year increase of 18.56% [2] - The basic earnings per share were 0.16 yuan, reflecting a year-on-year increase of 14.29% [2]

Core Viewpoint - The company reported a revenue of 41.188 billion yuan for the first half of 2025, reflecting a year-on-year growth of 3.54% [1] - The net profit attributable to shareholders reached 282 million yuan, marking an 18.56% increase compared to the previous year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 277 million yuan, showing a significant growth of 26.68% year-on-year [1] - The basic earnings per share stood at 0.16 yuan [1] Financial Performance - Revenue for the reporting period was 41.188 billion yuan, up 3.54% year-on-year [1] - Net profit attributable to shareholders was 282 million yuan, an increase of 18.56% [1] - Net profit after deducting non-recurring items was 277 million yuan, reflecting a growth of 26.68% [1] - Basic earnings per share were reported at 0.16 yuan [1]

Core Insights - Guizhou Bailing reported a significant decline in both revenue and net profit for the first half of 2025, with revenue at 1.46 billion yuan, down 31.77% year-on-year, and net profit at 52 million yuan, down 40.73% [1][2]. Financial Performance - Total revenue for the reporting period was 1,461,977,449.93 yuan, compared to 2,142,835,969.60 yuan in the same period last year, reflecting a decrease of 31.77% [2][3]. - Net profit attributable to shareholders was 51,834,649.77 yuan, down from 87,461,409.09 yuan, marking a decline of 40.73% [2][3]. - The net profit after deducting non-recurring gains and losses was 13,845,766.20 yuan, a decrease of 57.48% from 32,563,183.46 yuan [2]. - Basic and diluted earnings per share both decreased by 33.33% to 0.04 yuan [2]. - The weighted average return on equity was 1.62%, down from 2.50% [2]. Cash Flow and Assets - The net cash flow from operating activities was 249,349,377.36 yuan, a significant increase of 921.03% compared to -30,370,447.37 yuan in the previous year [2]. - Total assets at the end of the reporting period were 6,863,503,681.25 yuan, down 3.80% from the previous year [2]. Revenue Breakdown by Segment - The pharmaceutical industry remained a crucial support for Guizhou Bailing's performance, contributing over half of the total revenue [1]. - Revenue from the industrial segment was 823,121,873.13 yuan, down 27.82% year-on-year [3]. - Revenue from the commercial segment was 595,118,100.12 yuan, down 37.84% [3]. - Revenue from medical institutions increased slightly to 33,130,122.43 yuan, up 2.21% [3]. - Other segments generated 10,607,354.25 yuan, down 15.89% [3]. Product Revenue Analysis - Revenue from traditional Chinese medicine was 1,271,416,424.40 yuan, a decrease of 37.07% [3]. - Revenue from Chinese medicinal materials increased significantly by 299.47% to 6,100,820.82 yuan [3]. - Revenue from other products rose by 121.55% to 27,939,307.54 yuan [3].

格隆汇8月20日丨重药控股(000950.SZ)公布2025年半年度报告，上半年公司实现营业收入411.88亿元， 同比增长3.54%；归属于上市公司股东的净利润2.82亿元，同比增长18.56%；归属于上市公司股东的扣 除非经常性损益的净利润2.77亿元，同比增长26.68%；基本每股收益0.16元。 ...